Madison Square Garden Azioni (NYSE: MSGE)

Madison Square Garden (NYSE:MSGE) Azioni

MADISON SQUARE GARDEN ENTERT

Madison Square Garden

Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden Entertainment Corp

SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>) reported quarterly earnings of $0.40 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $53.913 million which beat the analyst consensus estimate of $53.551 million by 0.68 percent. This is a 8.59 percent decrease over sales of $58.978 million the same period last year.

Earnings

Earnings Beats

News

SLRC

CORRECTION: SLR Inv Q2 EPS $0.40, Inline, Sales $53.913M Beat $53.551M Estimate

Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) has outperformed the market over the past 10 years by 2.02% on an annualized basis producing an average annual return of 13.67%. Currently, Marriott International has a market capitalization of $71.52 billion. 
Buying $100 In MAR: If an investor had bought $100 of MAR stock 10 years ago, it would be worth $357.99 today based on a price of $259.72 for MAR at the time of writing.
<h3>Marriott International's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754433020_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Marriott International Stock In The Last 10 Years

Outfront Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.24 by 10.2 percent. This is a 22.22 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $460.200 million which missed the analyst consensus estimate of $463.164 million by 0.64 percent. This is a 3.58 percent decrease over sales of $477.300 million the same period last year.

Earnings Misses

UPDATE: Outfront Media Q2 Adj. EPS $0.22 Misses $0.24 Estimate, Sales $460.200M Miss $463.164M Estimate

Jones Trading analyst Matthew Erdner maintains Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) with a Buy and maintains $10.5 price target.

Price Target

Analyst Ratings

AOMR

Jones Trading Maintains Buy on Angel Oak Mortgage REIT, Maintains $10.5 Price Target

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and maintains $82 price target.

CRSP

Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $82 Price Target

Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.71 by 28.37 percent. This is a 5.56 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $3.540 billion which beat the analyst consensus estimate of $3.124 billion by 13.33 percent. This is a 25.67 percent increase over sales of $2.817 billion the same period last year.

CORRECTION: Mosaic Q2 Adj. EPS $0.51 Misses $0.71 Estimate, Sales $3.540B Beat $3.124B Estimate

Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.09 by 631.18 percent. The company reported quarterly sales of $139.098 million which beat the analyst consensus estimate of $125.561 million by 10.78 percent.

HNGE

CORRECTION: Hinge Health Q2 Adj. EPS $0.68 Beats $0.09 Estimate, Sales $139.098M Beat $125.561M Estimate

Zeta Global Holdings Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) shares are moving higher in Tuesday&#8217;s after-hours session after the company reported better-than-expected results and<a href="https://www.benzinga.com/pressreleases/25/08/b46871073/zeta-global-reports-16th-straight-beat-and-raise-quarter"> raised its full-year 2025 guidance</a>.
ZETA stock is on the move, climbing higher. <a href="https://www.benzinga.com/quote/ZETA" target="_blank" rel="noreferrer noopener">See the chart here.</a>
What Happened: Zeta reported second-quarter revenue of $308.44 million, beating analyst <a href="http://benzinga.com/quote/ZETA/earnings">estimates</a> of $296.65 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The AI marketing cloud company said total revenue was up 35% on a year-over-year basis. Zeta generated $42 million of operating cash flow and $34 million of free cash flow during the quarter. 
Zeta&#8217;s board approved a new stock repurchase program of up to $200 million over the next two years. The company now has $215 million in approved buybacks remaining. Zeta ended the quarter with $365.31 million in cash and cash equivalents. 
&#8220;We delivered another quarter of industry-leading growth, fueled by demand for our AI-powered marketing platform,&#8221; said David Steinberg, co-founder, chairman and CEO of Zeta. 
&#8220;As we head into the back half of 2025, our AI-driven momentum on the heels of the Zeta Answers release, new Zeta Marketing Platform deployments, agency expansions and OneZeta wins gives us conviction that Zeta is poised to capture even more market share.&#8221;
Guidance: Zeta expects third-quarter revenue of $327 million to $329 million versus estimates of $323.24 million. The company also raised its full-year 2025 revenue guidance from a range of $1.237 billion to $1.247 billion to a new range of $1.258 billion to $1.268 billion versus <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates of $1.241 billion. 
ZETA Price Action: <a href="http://benzinga.com/quote/ZETA">Zeta Global shares</a> were up 5.17% in Tuesday&#8217;s after-hours session, trading at $16.69 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/08/46875089/astera-labs-stock-soars-after-q2-results-heres-why">Astera Labs Stock Soars After Q2 Results: Here&#8217;s Why</a></li>
</ul>
Photo: Piotr Swat/Shutterstock.com

Guidance

After-Hours Center

Movers

Tech

ZETA

Zeta Global Stock Is Rising After Q2 Earnings, Company Highlights 'AI-Driven Momentum'

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 1.59% on an annualized basis producing an average annual return of 13.23%. Currently, Thermo Fisher Scientific has a market capitalization of $175.96 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $3,400.06 today based on a price of $466.42 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754432133_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today

SMCI

Super Micro Computer Q4 FY2025 Earnings Call Transcript

Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.14 by 12.68 percent. This is a 166.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $58.350 million which beat the analyst consensus estimate of $53.025 million by 10.04 percent. This is a 26.43 percent increase over sales of $46.152 million the same period last year.

UPDATE: Flotek Industries Q2 Adj. EPS $0.16 Beats $0.14 Estimate, Sales $58.350M Beat $53.025M Estimate

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly earnings of $0.02 per share. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported $10.838 million in sales this quarter. This is a 10.04 percent increase over sales of $9.849 million the same period last year.

CPIX

CORRECTION: Cumberland Q2 Adj. EPS $0.02 Up From $0.01 YoY, Sales $10.838M Up From $9.849M YoY

Dating app company Match Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) reported second-quarter financial results<a href="https://www.benzinga.com/earnings"> after market close Tuesday.</a>
MTCH stock is up after-hours. <a href="https://www.benzinga.com/quote/MTCH" target="_blank" rel="noreferrer noopener">Track it now here.</a>
Here are the key highlights
What Happens: Match Group reported second-quarter revenue of $864 million, flat year-over-year. The revenue total beat a Street consensus estimate of $853.76 million according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0805"> from Benzinga Pro.</a>
The company reported earnings per share of 49 cents, which was in-line with Street estimates.
Match's Payers were down 5% year-over-year to 14.1 million, but the company recognized a higher revenue per payer of $20.00.
The company said Hinge saw monthly active users up around 20% year-over-year with user growth of 60% year-over-year in European Expansion markets. Hinge's new AI algorithm is helping increase matches and contact exchanges.
"Six months ago, we took a hard look at how we work, what we build, and what users want from our apps," Match Group CEO Spencer Rascoff said. "We moved fast to reset the company culturally, organizationally, and strategically."
Read Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46230517/app-store-fee-cuts-set-to-boost-duolingo-match-bumble-earnings">App Store Fee Cuts Set To Boost Duolingo, Match, Bumble Earnings</a>
What's Next: Rascoff said there has been "meaningful product progress at Tinder" along with momentum at Hinge, which are helping the company position for long-term success.
"As we look ahead to our resurgence phase in 2026 and 2027, we are focused on delivering app experiences that feel modern, human and built for today's users," Rascoff said. "We are also working to spark a resurgence of trust, relevance, and confidence among both our users and investors."
The company plans on reinvesting savings of $50 million in the second half into strategic initiatives across the company's portfolio. This includes product testing at Tinder and geographic expansion for some other apps like Hinge. Match also said a new dating concept would get some of the investment.
The company is guiding for third quarter revenue of $910 million to $920 million, up 2% to 3% year-over-year. The revenue guidance is higher than a Street estimate of $889.21 million, according to data from Benzinga Pro.
MTCH Price Action: Match stock is up 4.50% to $35.25 in after-hours trading Tuesday versus a 52-week trading range of $26.39 to $38.77.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46097698/bumble-is-breaking-up-with-30-staff-investors-swipe-right">Bumble Is &#8216;Breaking Up&#8217; With 30% Staff, Investors Swipe Right</a></li>
</ul>
Photo: Shutterstock

Social Media

MTCH

Match Group Investors Swipe Right On Q2 Results, Q3 Guidance

Analysts' ratings for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a high estimate of $107.00, and a low estimate of $68.00. A decline of 13.85% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1754431450_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Eastman Chemical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$74.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$101.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$107.00</td>
<td>$111.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Eastman Chemical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Eastman Chemical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>Delving into Eastman Chemical's Background</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Unraveling the Financial Story of Eastman Chemical</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Eastman Chemical's financials over 3M reveals challenges. As of 30 June, 2025, the company experienced a decline of approximately -3.22% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Eastman Chemical's net margin excels beyond industry benchmarks, reaching 6.12%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eastman Chemical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.39% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Eastman Chemical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.93%, the company showcases efficient use of assets and strong financial health.
Debt Management: Eastman Chemical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.88.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Eastman Chemical: Insights From 8 Analyst Reviews

In the last three months, 7 analysts have published ratings on Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $223.57, a high estimate of $260.00, and a low estimate of $188.00. This upward trend is apparent, with the current average reflecting a 3.85% increase from the previous average price target of $215.29.
<img src="https://www.benzinga.com/files/images/story/2025/1754431442_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Allstate's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$202.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$198.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$237.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$188.00</td>
<td>$172.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allstate. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allstate compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Allstate's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Allstate's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allstate analyst ratings.</a>
<h2>Delving into Allstate's Background</h2>
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
<h3>Allstate: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Allstate's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 5.68%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Allstate's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 12.51%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Allstate's ROA stands out, surpassing industry averages. With an impressive ROA of 1.8%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.37, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Assess Allstate: What You Need To Know

During the last three months, 8 analysts shared their evaluations of Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.62, with a high estimate of $42.00 and a low estimate of $35.00. This current average reflects an increase of 5.46% from the previous average price target of $36.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1754431394_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Lincoln National by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lincoln National. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lincoln National compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Lincoln National's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Lincoln National's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lincoln National analyst ratings.</a>
<h2>All You Need to Know About Lincoln National</h2>
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.
<h3>Understanding the Numbers: Lincoln National's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Lincoln National's revenue growth over a period of 3M has faced challenges. As of 30 June, 2025, the company experienced a revenue decline of approximately -11.5%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Lincoln National's net margin is impressive, surpassing industry averages. With a net margin of 16.93%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Lincoln National's ROE stands out, surpassing industry averages. With an impressive ROE of 8.73%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Lincoln National's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.18%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Lincoln National's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.67, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lincoln National Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

Across the recent three months, 12 analysts have shared their insights on BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated BioNTech and provided 12-month price targets. The average target is $134.42, accompanied by a high estimate of $155.00 and a low estimate of $110.00. Highlighting a 2.85% decrease, the current average has fallen from the previous average price target of $138.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1754431383_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of BioNTech's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$126.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$138.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$116.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$134.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$134.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BioNTech. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of BioNTech's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of BioNTech's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BioNTech analyst ratings.</a>
<h2>All You Need to Know About BioNTech</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>BioNTech: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining BioNTech's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.56% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: BioNTech's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -227.46%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BioNTech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): BioNTech's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.9%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.02, BioNTech adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNTX

Breaking Down BioNTech: 12 Analysts Share Their Views

HONG KONG, HK / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / August 5, 2025 / Tianci International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIIT#NASDAQ">CIIT</a>) ("Tianci") announced today that it has signed an agreement to purchase 5,000 DMT ("dry metric tons") of chromite ore concentrate through its Hong Kong subsidiary, Roshing International Co., Limited. This agreement represents Tianci's first step in entering the international market for mineral resources business.
Tianci purchased this batch of high-quality chromite ore concentrate from a well-established supplier. Tianci's inspection of the ore was strictly carried out in accordance with international standards that revealed a chromium concentration ranging from 46% to 50%.
Following extensive market research and discussions with potential suppliers, Tianci now plans to expand its global shipping network and optimize its supply chain structure to respond to market demand for high-quality mineral resources. Management looks upon this plan to integrate participation in the mineral trade with Tianci's global shipping resources as a vehicle to strengthen Tianci's market competitiveness and enhance its influence within shipping industry.
 &nbsp;

CIIT

Tianci International Signs An Agreement To Purchase 5,000 Dry Metric Tons Of Chromite Ore Concentrate

In the last three months, 15 analysts have published ratings on Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $72.27, along with a high estimate of $78.00 and a low estimate of $64.00. This current average reflects an increase of 7.62% from the previous average price target of $67.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1754431321_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cisco Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Shiwen Li</td>
<td>CICC</td>
<td>Announces</td>
<td>Outperform</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Niknam</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$64.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$66.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cisco Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cisco Systems compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Cisco Systems's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cisco Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CSCO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cisco Systems analyst ratings.</a>
<h2>About Cisco Systems</h2>
Cisco Systems is the largest provider of networking equipment in the world and one of the largest software companies in the world. Its largest businesses are selling networking hardware and software (where it has leading market shares) and cybersecurity software such as firewalls. It also has collaboration products, like its Webex suite, and observability tools. It primarily outsources its manufacturing to third parties and has a large sales and marketing staff—25,000 strong across 90 countries. Overall, Cisco employs 80,000 people and sells its products globally.
<h3>Cisco Systems: Financial Performance Dissected</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Cisco Systems displayed positive results in 3M. As of 30 April, 2025, the company achieved a solid revenue growth rate of approximately 11.39%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 17.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.45%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cisco Systems's ROA excels beyond industry benchmarks, reaching 2.07%. This signifies efficient management of assets and strong financial health.
Debt Management: Cisco Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.64.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSCO

Assessing Cisco Systems: Insights From 15 Financial Analysts

In the current session, the stock is trading at $14.36, after a 2.50% spike. Over the past month, MRC Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) stock increased by 7.97%, and in the past year, by 14.88%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1754431267_0_0.png" alt="Past Year Chart" />

<h3>A Look at MRC Global P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 49.83 in the Trading Companies &amp; Distributors industry, MRC Global Inc. has a lower P/E ratio of 28.02. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1754431268_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into MRC Global Inc's Price Over Earnings

Entertainment

Press Releases

General

Madison Square Garden Entertainment Corp. to Host Fiscal 2025 Second Quarter Conference Call

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2025 SECOND QUARTER RESULTS

THE MSG FAMILY OF COMPANIES AND PEPSICO EXPAND MULTI-YEAR PARTNERSHIP

THE RADIO CITY ROCKETTES CELEBRATE 100 YEARS OF PRECISION, ATHLETICISM & SISTERHOOD IN 2025

THE MSG FAMILY OF COMPANIES ANNOUNCE INTEGRATED MARKETING PARTNERSHIP WITH LIQUID DEATH

MSG ENTERTAINMENT NAMES DAVID COLLINS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER

SNAPPLE® NAMED OFFICIAL TEA PARTNER OF THE NEW YORK KNICKS, NEW YORK RANGERS AND MADISON SQUARE GARDEN

Real Estate

Madison Square Garden Entertainment Corp. to Host Fiscal 2025 Third Quarter Conference Call

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2025 THIRD QUARTER RESULTS

Celebrate the Rockettes 100th Anniversary at the 2025 Christmas Spectacular!

MSGE

MSGS

SPHR

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Liberty Media

Ordinary Shares (New Liberty Formula One) Series A

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

K Wave Media

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

Madison Square Garden

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO